| Literature DB >> 23922661 |
Hongyan Xu1, Siew Hong Lam, Yuan Shen, Zhiyuan Gong.
Abstract
Inorganic arsenic is a worldwide metalloid pollutant in environment. Although extensive studies on arsenic-induced toxicity have been conducted using in vivo and in vitro models, the exact molecular mechanism of arsenate toxicity remains elusive. Here, the RNA-SAGE (serial analysis of gene expression) sequencing technology was used to analyse hepatic response to arsenic exposure at the transcriptome level. Based on more than 12 million SAGE tags mapped to zebrafish genes, 1,444 differentially expressed genes (750 up-regulated and 694 down-regulated) were identified from a relatively abundant transcripts (>10 TPM [transcripts per million]) based on minimal two-fold change. By gene ontology analyses, these differentially expressed genes were significantly enriched in several major biological processes including oxidation reduction, translation, iron ion transport, cell redox, homeostasis, etc. Accordingly, the main pathways disturbed include metabolic pathways, proteasome, oxidative phosphorylation, cancer, etc. Ingenity Pathway Analysis further revealed a network with four important upstream factors or hub genes, including Jun, Kras, APoE and Nr2f2. The network indicated apparent molecular events involved in oxidative stress, carcinogenesis, and metabolism. In order to identify potential biomarker genes for arsenic exposure, 27 out of 29 up-regulated transcripts were validated by RT-qPCR analysis in pooled RNA samples. Among these, 14 transcripts were further confirmed for up-regulation by a lower dosage of arsenic in majority of individual zebrafish. Finally, at least four of these genes, frh3 (ferrintin H3), mgst1 (microsomal glutathione S-transferase-like), cmbl (carboxymethylenebutenolidase homolog) and slc40a1 (solute carrier family 40 [iron-regulated transporter], member 1) could be confirmed in individual medaka fish similarly treated by arsenic; thus, these four genes might be robust arsenic biomarkers across species. Thus, our work represents the first comprehensive investigation of molecular mechanism of asenic toxicity and genome-wide search for potential biomarkers for arsenic exposure.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23922661 PMCID: PMC3726666 DOI: 10.1371/journal.pone.0068737
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Comparison of transcriptomic profiles between arsenic-treated and control groups.
(A) Distribution of transcript entries and total transcript counts in both arsenic-treated and control groups. The percentages of accumulated transcript counts or transcript entries are plotted over different transcript abundance categories. (B) Plot of transcript change fold (Y-axis) versus transcript TPM (X-axis) after arsenic exposure. Both axes are in log2 scale and TPM in the X-axis is based on the treatment group.
Significantly affected gene ontology terms by arsenic exposure.
| Category | Term | Count | Enrichment | p-Value |
|
| GO:0055114∼oxidation reduction | 78 | 1.79 | 3.330E-04 |
|
| GO:0006412∼translation | 48 | 2.14 | 3.759E-04 |
| GO:0042592∼homeostatic process | 33 | 2.42 | 1.384E-03 | |
| GO:0019725∼cellular homeostasis | 25 | 2.56 | 7.568E-03 | |
| GO:0006508∼proteolysis | 73 | 1.54 | 3.378E-02 | |
| GO:0006826∼iron ion transport | 8 | 5.79 | 3.821E-02 | |
| GO:0045454∼cell redox homeostasis | 15 | 3.10 | 3.473E-02 | |
|
| GO:0005506∼iron ion binding | 48 | 2.25 | 8.657E-05 |
|
| GO:0003735∼structural constituent of ribosome | 30 | 2.49 | 1.759E-03 |
| GO:0005198∼structural molecule activity | 51 | 1.89 | 2.429E-03 | |
| GO:0070011∼peptidase activity, acting on L-amino acid peptides | 62 | 1.73 | 2.944E-03 | |
| GO:0008233∼peptidase activity | 63 | 1.68 | 5.511E-03 | |
| GO:0008235∼metalloexopeptidase activity | 10 | 4.72 | 1.218E-02 | |
| GO:0004866∼endopeptidase inhibitor activity | 18 | 2.83 | 1.112E-02 | |
| GO:0008199∼ferric iron binding | 7 | 6.89 | 1.555E-02 | |
| GO:0008238∼exopeptidase activity | 13 | 3.34 | 2.094E-02 | |
| GO:0030170∼pyridoxal phosphate binding | 13 | 3.20 | 2.872E-02 | |
| GO:0070279∼vitamin B6 binding | 13 | 3.20 | 2.872E-02 | |
| GO:0004298∼threonine-type endopeptidase activity | 9 | 4.43 | 2.880E-02 | |
| GO:0070003∼threonine-type peptidase activity | 9 | 4.43 | 2.880E-02 | |
| GO:0030414∼peptidase inhibitor activity | 18 | 2.53 | 2.695E-02 | |
| GO:0016769∼transferase activity, transferring nitrogenous groups | 10 | 3.81 | 3.457E-02 | |
| GO:0004857∼enzyme inhibitor activity | 20 | 2.27 | 4.203E-02 | |
|
| GO:0005739∼mitochondrion | 50 | 2.25 | 1.033E-05 |
|
| GO:0005840∼ribosome | 35 | 2.49 | 7.856E-05 |
| GO:0005829∼cytosol | 26 | 2.58 | 1.094E-03 | |
| GO:0030529∼ribonucleoprotein complex | 41 | 1.86 | 6.125E-03 | |
| GO:0000502∼proteasome complex | 14 | 3.46 | 5.464E-03 | |
| GO:0044429∼mitochondrial part | 29 | 2.10 | 7.570E-03 | |
| GO:0005839∼proteasome core complex | 9 | 4.54 | 1.565E-02 | |
| GO:0043232∼intracellular non-membrane-bounded organelle | 79 | 1.42 | 1.907E-02 | |
| GO:0043228∼non-membrane-bounded organelle | 79 | 1.42 | 1.907E-02 | |
| GO:0005740∼mitochondrial envelope | 25 | 2.07 | 1.949E-02 |
Note: Count is number of genes involved. Fold Enrichment is (m/n)/(M/N), where N = all genes in zebrafish, M = all genes belonging to a GO term, n = genes from the differentially expressed gene set, m = genes from the differentially expressed gene set belonging to a GO term.
Figure 2Diseases inferred by IPA based on differentially expressed genes after arsenic exposure.
The bar chart shows the number of arsenic-deregulated genes matched in different disease or disorder categories and only top significant categories (P<0.01) were selected to show. The same gene may be assigned to more than one categories.
Figure 3Key upstream regulator networks modulated by arsenic exposure.
The upstream network was generated by IPA and the networks indicate predicted upstream regulators and their downstream target genes presented in the differentially expressed gene set. Up-regulated genes are in red and down-regulated in green. Solid arrow lines represent direct interaction while dotted lines indirect intereaction.
Enriched KEGG pathways identified by Gene Set Enricher of CTD.
| Pathways | Pathway ID | P-value | Gene counts |
| *Metabolic pathways | KEGG:01100 | 3.99E-49 | 142 |
| *Proteasome (folding, sorting & degradation) | KEGG:03050 | 1.58E-11 | 16 |
| Glycine, serine and threonine metabolism | KEGG:00260 | 1.05E-08 | 12 |
| Glycolysis/gluconeogenesis | KEGG:00010 | 1.10E-06 | 14 |
| *Arginine & proline metabolism | KEGG:00330 | 1.41E-06 | 13 |
| *Glutathione Metabolism | KEGG:00480 | 4.05E-06 | 12 |
| *Protein processing in endoplasmic reticulum | KEGG:04141 | 4.20E-06 | 21 |
| Tryptophan metabolism | KEGG:00380 | 7.15E-06 | 11 |
| *PPAR signaling pathways | KEGG:03320 | 2.02E-05 | 13 |
| Oxidative phosphorylation | KEGG:00190 | 2.79E-05 | 17 |
| Ribosome | KEGG:03010 | 7.19E-05 | 14 |
| *Pathways in cancer | KEGG:05200 | 9.58E-05 | 27 |
| *MAPK signaling pathway | KEGG:04010 | 1.77E-04 | 24 |
| *Hepatitis C | KEGG:05160 | 2.52E-04 | 16 |
| Purine metabolism | KEGG:00230 | 3.45E-04 | 18 |
| Bladder cancer | KEGG:05219 | 3.68E-04 | 9 |
| Proximal tubule bicarbonate reclamation | KEGG:04964 | 4.41E-04 | 7 |
| Peroxisome | KEGG:04146 | 4.95E-04 | 12 |
| Propanoate metabolism | KEGG:00640 | 6.76E-04 | 8 |
| Fat digestion and absorption | KEGG:04975 | 0.00143 | 9 |
| *Ubiquitin mediated proteolysis | KEGG:04120 | 0.00162 | 15 |
| Antigen processing and presentation | KEGG:04612 | 0.00192 | 11 |
| *Cardiac muscle contraction | KEGG:04260 | 0.00218 | 11 |
| *Cell cycle | KEGG:04110 | 0.00261 | 14 |
| *Mineral absorption | KEGG:04978 | 0.00281 | 9 |
| *Endometrial cancer | KEGG:05213 | 0.0033 | 9 |
| Parkinson's disease | KEGG:05012 | 0.00341 | 14 |
| *Huntington | KEGG:05016 | 0.00381 | 17 |
| Complement and coagulation cascades | KEGG:04610 | 0.00447 | 10 |
| *Leukocyte transendothelial migration | KEGG:04670 | 0.0046 | 13 |
| *Carbohydrate digestion and absorption | KEGG:04973 | 0.00522 | 8 |
| Pyrimidine metabolism | KEGG:00240 | 0.00549 | 12 |
| TCA cycle | KEGG:00020 | 0.00609 | 7 |
| Pyruvate metabolism | KEGG:00620 | 0.0062 | 8 |
| *Prostate cancer | KEGG:05215 | 0.00856 | 11 |
| *Insulin signaling | KEGG:04910 | 0.00914 | 14 |
Note: Pathways indicated with asterisks are newly identified in the present study.
Figure 4Preliminary identification of potential biomarker genes for arsenic exposure.
Selected up-regulated genes by arsenic exposure were examined by RT-qPCR in individual zebrafish (A) and medaka (B) after treatment with arsenic. (A), Fold changes (log2 ratio) of 14 up-regulated genes measured by RT-qPCR. S1-S9, 9 individual zebrafish treated with 15 ppm sodium; 15 ppm, average of the 9 individual fish; 20 ppm, RT-qPCR measurement from the pooled RNA sample used for RNA-SAGE sequencing; SAGE, RNA-SAGE data for comparison (Log2 fold change). The 9 genes displayed dosage-dependent effect between 15 ppm and 20 ppm are indicated with asterisks. Zebrafish gene symbols and names are shown based on NCBI and underlined genes are annotated manually. (B), Average of fold changes (log2 ratio) of four validated medaka genes in 4 individual medaka fish. (C) Comparison of the expression of arsenic biomarker genes in other chemical treatments by hierarchical clustering heatmap. RNA-SAGE data from the current study (Arsenic) were compared with hepatic RNA-SAGE data from zebrafish treated with 5 µg/L 17β-estradiol (E2), 5 µg/L 11-keto testosterone (KT11) or 10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The left clustering is based on the 14 genes identified from zebrafish and the right based on the four genes from both zebrafish and medaka.